---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-20T14:57:14.612824'
end_time: '2026-02-20T15:10:58.274109'
duration_seconds: 823.66
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: HSPB6
  gene_symbol: HSPB6
  uniprot_accession: O14558
  protein_description: 'RecName: Full=Heat shock protein beta-6; Short=HspB6; AltName:
    Full=Heat shock 20 kDa-like protein p20; AltName: Full=Heat shock protein family
    B member 6;'
  gene_info: Name=HSPB6;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the small heat shock protein (HSP20) family.
  protein_domains: A-crystallin/Hsp20_dom. (IPR002068); Alpha-crystallin/sHSP_animal.
    (IPR001436); Alpha-crystallin_N. (IPR003090); HSP20-like_chaperone. (IPR008978);
    Crystallin (PF00525)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 22
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O14558
- **Protein Description:** RecName: Full=Heat shock protein beta-6; Short=HspB6; AltName: Full=Heat shock 20 kDa-like protein p20; AltName: Full=Heat shock protein family B member 6;
- **Gene Information:** Name=HSPB6;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the small heat shock protein (HSP20) family.
- **Key Domains:** A-crystallin/Hsp20_dom. (IPR002068); Alpha-crystallin/sHSP_animal. (IPR001436); Alpha-crystallin_N. (IPR003090); HSP20-like_chaperone. (IPR008978); Crystallin (PF00525)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "HSPB6" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'HSPB6' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **HSPB6** (gene ID: HSPB6, UniProt: O14558) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O14558
- **Protein Description:** RecName: Full=Heat shock protein beta-6; Short=HspB6; AltName: Full=Heat shock 20 kDa-like protein p20; AltName: Full=Heat shock protein family B member 6;
- **Gene Information:** Name=HSPB6;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the small heat shock protein (HSP20) family.
- **Key Domains:** A-crystallin/Hsp20_dom. (IPR002068); Alpha-crystallin/sHSP_animal. (IPR001436); Alpha-crystallin_N. (IPR003090); HSP20-like_chaperone. (IPR008978); Crystallin (PF00525)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "HSPB6" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'HSPB6' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **HSPB6** (gene ID: HSPB6, UniProt: O14558) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Title: Functional Annotation Research Report — Human HSPB6 (HspB6/HSP20; UniProt O14558)

Publication date: 2026-02-20

1. Target identity verification (required disambiguation)

HSPB6 is consistently described in the biomedical literature as the small heat shock protein also known as HSP20/Hsp20, with strong constitutive expression in muscle tissues and regulation by Ser16 phosphorylation, matching the UniProt identity provided (O14558; “heat shock protein beta-6”, small HSP family). (komalavilas2008thesmallheat pages 2-4, komalavilas2008thesmallheat pages 1-2)

2. Key concepts, definitions, and current understanding

2.1. What HSPB6 is (protein class and general role)

HSPB6 (Hsp20) belongs to the small heat shock protein (sHSP/HSPB) family. Functionally, sHSPs are ATP-independent “holdase” chaperones that can modulate proteostasis by binding aggregation-prone proteins and, in some contexts, regulating cytoskeletal organization and stress resistance. HSPB6 is distinctive among HSPBs for its prominent roles in muscle physiology (smooth muscle relaxation/“force suppression”) and in stress protection in cardiovascular contexts. (mymrikov2011largepotentialsof pages 14-16, mymrikov2011largepotentialsof pages 16-17)

2.2. Core regulatory concept: Ser16 phosphorylation as a signaling-controlled functional switch

A central concept for HSPB6 biology is phosphorylation at Ser16 by cyclic nucleotide-dependent kinases (PKA and PKG), which is repeatedly reported to correlate with smooth muscle relaxation and “force suppression”—relaxation that occurs without the canonical requirement for myosin light chain (MLC) dephosphorylation. (flynn2005transductionofphosphorylated pages 1-2, mymrikov2011largepotentialsof pages 14-16)

2.3. “Force suppression” and thin-filament / cytoskeletal mechanisms

Force suppression refers to cyclic nucleotide-mediated smooth muscle relaxation without reductions in MLC phosphorylation. Mechanistic models summarized in authoritative review literature include: (i) conformational change after Ser16 phosphorylation that functionally inactivates thin filaments and inhibits myosin binding; and (ii) phosphorylation-dependent remodeling of actin dynamics through changes in HSPB6 association with actin pools and actin-associated proteins. (mymrikov2011largepotentialsof pages 14-16)

3. Molecular mechanisms and pathway placement

3.1. Upstream signaling: cAMP/PKA and cGMP/PKG converge on HSPB6 Ser16

Primary experimental studies show that cAMP-elevating stimuli (e.g., β-agonist isoproterenol; forskolin) increase HSPB6 Ser16 phosphorylation in smooth muscle cells and correlate with relaxation. PKA dependence is supported by inhibition experiments (e.g., PKI-GFP expression blocking stimulus-dependent phosphorylation). (komalavilas2008thesmallheat pages 1-2, komalavilas2008thesmallheat pages 2-4)

In vascular smooth muscle, HSPB6 Ser16 is described as phosphorylated by PKA and PKG, functioning as a convergence node for cAMP/cGMP-mediated relaxation signaling. (flynn2005transductionofphosphorylated pages 1-2)

3.2. Key interaction partner: 14-3-3 proteins link phospho-HSPB6 to actin remodeling

HSPB6 contains a 14-3-3-binding motif, and phosphorylated HSPB6 binds 14-3-3γ, whereas non-phosphorylated HSPB6 or phosphorylation-insensitive Ser16 mutants do not. This provides a mechanistic route by which phosphorylation acts as a “molecular switch” enabling specific adaptor binding. (komalavilas2008thesmallheat pages 2-4)

3.3. Downstream effector axis: phospho-HSPB6 ↔ 14-3-3 ↔ cofilin → actin depolymerization

A supported mechanistic model is competitive binding at 14-3-3: phospho-HSPB6 binds 14-3-3 and can displace phosphorylated cofilin from 14-3-3. Release of cofilin allows its dephosphorylation/activation (e.g., via slingshot phosphatase pathways), promoting actin filament fragmentation and depolymerization. This actin remodeling is tied to reduced stress fibers, focal adhesion disruption, and smooth muscle relaxation. (komalavilas2008thesmallheat pages 2-4, mymrikov2011largepotentialsof pages 17-18)

Experimental visual evidence consistent with this model includes figures showing increased phospho-HSP20 (Ser16) with concomitant decreased phospho-cofilin under PKA agonists, and actin stress-fiber disruption after PKA agonists or phospho-HSP20 peptide treatment in airway smooth muscle models. (komalavilas2008thesmallheat media 8afe3440, komalavilas2008thesmallheat media 4577aba1)

3.4. HSPB6 association with actin/α-actinin and phosphorylation-dependent dissociation

HSPB6 has been reported to associate with actin and α-actinin; Ser16 phosphorylation correlates with dissociation of HSPB6 from actin and α-actinin and with partial actin depolymerization and cytoskeletal reorganization leading to relaxation. Quantitatively, cosedimentation studies cited in an authoritative review indicate low stoichiometry binding to actin (monomer HSPB6/monomer actin < 0.04). (mymrikov2011largepotentialsof pages 16-17)

3.5. Subcellular localization context

In smooth muscle, HSPB6 is described as predominantly cytosolic, with only a small fraction cytoskeleton-bound under basal conditions. Concentration estimates in an authoritative review place total actin in smooth muscle at ~1,100 M (as reported) and HSPB6 monomer concentration in the ~100–200 M range, reinforcing the concept that HSPB6 is abundant but not present at near-stoichiometric levels with actin monomers. (mymrikov2011largepotentialsof pages 16-17)

3.6. Cardiomyocyte stress protection and contractility pathways (PPP1/PLN; autophagy axis)

Beyond smooth muscle, HSPB6 has been linked to cardiomyocyte survival pathways. An authoritative review summarizes that overexpression of HSPB6 in cardiomyocytes can prevent isoproterenol-induced apoptosis and protect against ischemia/reperfusion injury, with phosphomimetic S16D being more effective than wild-type in apoptosis prevention; reported correlates include higher Bcl-2/Bax ratio and reduced caspase-3 activity. (mymrikov2011largepotentialsof pages 17-18)

In a disease-mutation context, the S10F variant is associated with altered interaction with PPP1 (protein phosphatase 1), impacting the PPP1–phospholamban (PLN) axis described for HSPB6 in regulating Ca2+ handling/contractility in cardiomyocytes, and it is also linked to BECN1/Beclin-1-regulated autophagy (see Section 5). (liu2018regulationofbecn1mediated pages 5-9, liu2018regulationofbecn1mediated pages 1-5)

4. Recent developments and latest research (prioritized 2023–2024)

4.1. 2024: HSPB6 as a lipid-dependent chaperone modulating α-synuclein aggregation (Parkinson’s-relevant mechanism)

A key 2024 primary study (Secco et al., iScience, Sept 2024; https://doi.org/10.1016/j.isci.2024.110657) reports that HSPB6 shows lipid-dependent chaperone activity and can abrogate lipid-induced α-synuclein aggregation at low HSPB6:α-syn ratios in ThT assays, suggesting a mechanism primarily acting on membrane-associated aggregation steps rather than on fibril elongation in solution. (secco2024hspb6alipiddependent pages 7-9, secco2024hspb6alipiddependent pages 9-12)

Quantitative and mechanistic details from Secco et al. include:

• Experimental conditions for lipid-induced aggregation assays: SUVs at 100 µM; α-syn monomer 20 µM; pH 6.5; 30°C. (secco2024hspb6alipiddependent pages 9-12)

• At HSPB6:α-syn = 1:100 (0.2 µM:20 µM), HSPB6 abrogated aggregation across multiple lipid compositions; at 1:800 (0.025 µM:20 µM) inhibition was lost. (secco2024hspb6alipiddependent pages 9-12)

• HSPB6 lipid-binding affinities (Kd) to SUVs representing various organelle/compartment compositions were reported in the ~0.045–0.095 µM range, with examples including 0.045 (inner plasma membrane model), 0.062 (outer plasma membrane), 0.072 (mitochondria), 0.095 (ER), 0.088 (Golgi). (secco2024hspb6alipiddependent pages 9-12)

• Aggregation half-time changes correlated with HSPB6 lipid affinity at intermediate ratios (Pearson r = 0.85, p = 0.0375 at HSPB6:α-syn = 1:200), supporting a lipid-competition or lipid-embedded monomer shielding mechanism. (secco2024hspb6alipiddependent pages 9-12)

• Phosphorylation modulation: non-phosphorylatable S16A showed similar efficacy to wild-type in some lipid-induced aggregation contexts, while phosphomimetic S16D and chemically phosphorylated variants showed stronger inhibition, consistent with phosphorylation slightly enhancing the anti-aggregation effect. (secco2024hspb6alipiddependent pages 7-9)

Interpretation: This 2024 work expands HSPB6 functional annotation beyond muscle contractility into a mechanistically defined proteostasis role at membrane interfaces, providing quantitative parameters (Kd values and kinetic correlations) that could support future inhibitor/agonist design or biomarker hypotheses related to proteotoxic stress at cellular membranes. (secco2024hspb6alipiddependent pages 9-12)

4.2. 2024 review-level synthesis in neurodegeneration: phosphorylation-enhanced anti-aggregation effects for Aβ and α-syn

A 2025 review summarizing recent directions reports that HSPB6 can interact with Aβ in Alzheimer’s disease-related contexts and that phosphorylation enhances HSPB6 interaction with Aβ, with stronger phosphorylation dependence for fibrillar vs globular Aβ; similarly, phosphorylation can further enhance HSPB6 inhibition of lipid-induced α-synuclein aggregation. (This review discusses earlier primary work and frames it as recent progress in the field.) (albinhassan2025smallheatshock pages 14-16)

5. Disease relevance, human genetics, and systems-level evidence

5.1. Dilated cardiomyopathy (DCM) and the HSPB6 S10F variant (human genetics + mechanistic animal models)

Liu et al. (Autophagy, Jan 2018; https://doi.org/10.1080/15548627.2017.1392420) report a rare human HSPB6 coding variant S10F detected in DCM patients with an observed prevalence of 0.85% in screened patients, and rarity in population databases (ExAC: 3/6522 heterozygotes; 0.046%). (liu2018regulationofbecn1mediated pages 5-9)

In cardiac-specific transgenic mouse models overexpressing HSPB6S10F at ~10-fold, disease progression included:

• Progressive decline in systolic function with ejection fraction/fractional shortening reduced to ~50% by 16 months. (liu2018regulationofbecn1mediated pages 5-9)

• Increased ventricular volumes (LVESV ~2×; LVEDV ~1.5×), hypertrophy/fibrosis, and premature death (all n=21 transgenic mice dead by 18 months; mean lifespan 13.7 months vs 24–30 months in non-transgenic controls). (liu2018regulationofbecn1mediated pages 5-9)

Mechanistically, the S10F mutation is linked to impaired BECN1-mediated autophagy: mutant HSPB6 promotes BECN1 ubiquitination and proteasomal degradation, substantially inhibiting autophagic flux and increasing apoptosis, whereas wild-type HSPB6 increases BECN1 levels and enhances autophagy. (liu2018regulationofbecn1mediated pages 1-5, liu2018regulationofbecn1mediated pages 5-9)

5.2. Neurodegenerative disease mechanisms (aggregation/autophagy/unconventional secretion context)

A review focused on sHSPs in neurodegenerative disease notes that (i) HSPB6 was initially identified in skeletal muscle and is regarded as cardioprotective; (ii) the S10F variant can promote BECN1 ubiquitination and proteasomal degradation with autophagy inhibition and increased apoptosis; and (iii) recent work indicates HSPB6 has lipid-dependent chaperone activity that modulates α-synuclein aggregation, suggesting mechanistic relevance to Parkinson’s disease. (bonavita2025smallhspsat pages 6-7)

6. Current applications and real-world implementations

6.1. Smooth muscle relaxation as a translational platform: cell-permeant phospho-HSPB6 peptides and proteins

Multiple experimental studies summarized in an authoritative review describe engineered, cell-permeant phosphorylated HSPB6 constructs (short PTD-linked phospho-Ser16 peptides; full-length TAT-pHSP20) that enter cells and produce functional vasorelaxation, including:

• Relaxation of norepinephrine-precontracted rabbit aorta.

• Prevention of vasospasm in human umbilical artery (ex vivo human tissue model).

• Inhibition of contraction in rabbit aorta and human saphenous vein segments.

• Inhibition of platelet aggregation.

These results support a concrete translational “implementation” paradigm: targeting the HSPB6 Ser16-phospho pathway and its actin remodeling output using deliverable phospho-mimetics. (mymrikov2011largepotentialsof pages 16-17)

6.2. Anti-fibrotic/anti-scarring applications: AZX100

The same authoritative review describes a transducible phosphorylated peptide (AZX100) that reduced TGF-β1-induced CTGF and collagen expression in human keloid fibroblasts and improved collagen organization in a hamster scarring model, illustrating a broader application of the HSPB6 phospho-motif concept beyond acute vasorelaxation. (mymrikov2011largepotentialsof pages 16-17)

6.3. Drug discovery tooling: screening for compounds that disrupt HSPB6–14-3-3 binding

A fluorescence polarization assay has been developed to screen for compounds that compete with HSPB6 for 14-3-3 binding, representing an actionable assay framework for small-molecule modulation of the phospho-HSPB6→14-3-3 axis. (mymrikov2011largepotentialsof pages 17-18)

7. Relevant statistics and quantitative data (selected highlights)

• Actin-binding stoichiometry: monomer HSPB6/monomer actin < 0.04 (cosedimentation) (mymrikov2011largepotentialsof pages 16-17).

• Smooth muscle concentration estimates (as reported in an authoritative review): actin ~1,100 M; HSPB6 monomer ~100–200 M; HSPB6 predominantly cytosolic (mymrikov2011largepotentialsof pages 16-17).

• DCM genetics: S10F prevalence in screened DCM cohort 0.85%; ExAC prevalence 0.046% (3/6522) (liu2018regulationofbecn1mediated pages 5-9).

• DCM model phenotype (HSPB6S10F TG mice): EF/FS ~50% by 16 months; LVESV ~2×; LVEDV ~1.5×; all n=21 TG dead by 18 months; mean lifespan 13.7 months vs 24–30 months controls (liu2018regulationofbecn1mediated pages 5-9).

• 2024 lipid-dependent chaperone parameters: HSPB6 SUV-binding Kd values ~0.045–0.095 µM, and aggregation kinetics correlate with lipid affinity (r = 0.85, p = 0.0375) (secco2024hspb6alipiddependent pages 9-12).

8. Expert synthesis and analysis (evidence-based)

8.1. Unifying model of primary function

The most experimentally grounded “primary function” assignment for HSPB6 in human physiology is as a signaling-responsive regulator of actin cytoskeletal dynamics in muscle, coupling cyclic nucleotide signaling (PKA/PKG) to Ca2+-independent relaxation through Ser16 phosphorylation, adaptor binding to 14-3-3, and cofilin-mediated actin remodeling. This is supported by primary smooth muscle studies and is consolidated by a high-authority Physiological Reviews synthesis. (komalavilas2008thesmallheat pages 2-4, flynn2005transductionofphosphorylated pages 1-2, mymrikov2011largepotentialsof pages 16-17)

8.2. Expansion of functional annotation beyond muscle: membrane-interface proteostasis

The 2024 iScience study provides high-value new mechanistic specificity: HSPB6 can act as a lipid-dependent chaperone at membrane interfaces, with quantified lipid affinities and a statistically supported relationship between lipid binding and aggregation kinetics. This indicates that HSPB6’s functional scope is broader than contractility, and likely includes regulation of proteotoxicity where lipids and intrinsically disordered clients (e.g., α-synuclein) interact. (secco2024hspb6alipiddependent pages 9-12)

8.3. Disease mechanism plausibility

The S10F DCM-associated variant provides a mechanistically plausible disease link that does not rely only on correlation: impaired BECN1-mediated autophagy and increased apoptosis are shown in cellular and mouse models, alongside progressive cardiomyopathy and reduced survival. This supports a causal narrative where specific HSPB6 structural perturbations can shift the balance from protective stress responses (autophagy and cytoskeletal stabilization) to maladaptive proteostasis failure and cell death. (liu2018regulationofbecn1mediated pages 5-9, liu2018regulationofbecn1mediated pages 1-5)

9. Limitations of the present evidence set

This report focuses on evidence retrievable from the current tool-based corpus. Direct UniProt text and some highly recent 2024 cardiovascular primary studies (e.g., HSPB6 deficiency in aortic dissection) were not available in the retrieved full text set, limiting coverage of the newest cardiovascular genetics/knockout phenotypes. Consequently, disease landscape beyond DCM and mechanistic translation is incomplete and should be updated when those primary reports are accessible. (liu2018regulationofbecn1mediated pages 5-9)

References (URLs and publication dates)

• Flynn CR et al. “Transduction of phosphorylated heat shock-related protein 20, HSP20, prevents vasospasm of human umbilical artery smooth muscle.” Journal of Applied Physiology. May 2005. https://doi.org/10.1152/japplphysiol.01043.2004 (flynn2005transductionofphosphorylated pages 1-2)

• Komalavilas P et al. “The small heat shock-related protein, HSP20, is a cAMP-dependent protein kinase substrate that is involved in airway smooth muscle relaxation.” Am J Physiol Lung Cell Mol Physiol. Jan 2008. https://doi.org/10.1152/ajplung.00235.2007 (komalavilas2008thesmallheat pages 1-2, komalavilas2008thesmallheat pages 2-4)

• Mymrikov EV et al. “Large potentials of small heat shock proteins.” Physiological Reviews. Oct 2011. https://doi.org/10.1152/physrev.00023.2010 (mymrikov2011largepotentialsof pages 14-16, mymrikov2011largepotentialsof pages 16-17, mymrikov2011largepotentialsof pages 17-18)

• Liu G-S et al. “Regulation of BECN1-mediated autophagy by HSPB6: Insights from a human HSPB6S10F mutant.” Autophagy. Jan 2018. https://doi.org/10.1080/15548627.2017.1392420 (liu2018regulationofbecn1mediated pages 5-9, liu2018regulationofbecn1mediated pages 1-5)

• Secco V et al. “HSPB6: A lipid-dependent molecular chaperone inhibits α-synuclein aggregation.” iScience. Sept 2024. https://doi.org/10.1016/j.isci.2024.110657 (secco2024hspb6alipiddependent pages 9-12, secco2024hspb6alipiddependent pages 7-9)

• Bonavita R et al. “Small HSPs at the crossroad between protein aggregation, autophagy and unconventional secretion…” Frontiers in Cell and Developmental Biology. May 2025. https://doi.org/10.3389/fcell.2025.1538377 (bonavita2025smallhspsat pages 6-7)

• Albinhassan TH et al. “Small Heat Shock Proteins: Protein Aggregation Amelioration and Neuro- and Age-Protective Roles.” Int J Mol Sci. Feb 2025. https://doi.org/10.3390/ijms26041525 (albinhassan2025smallheatshock pages 14-16)

References

1. (komalavilas2008thesmallheat pages 2-4): Padmini Komalavilas, Raymond B. Penn, Charles R. Flynn, Jeffrey Thresher, Luciana B. Lopes, Elizabeth J. Furnish, Manhong Guo, Manuel A. Pallero, Joanne E. Murphy-Ullrich, and Colleen M. Brophy. The small heat shock-related protein, hsp20, is a camp-dependent protein kinase substrate that is involved in airway smooth muscle relaxation. American journal of physiology. Lung cellular and molecular physiology, 294 1:L69-78, Jan 2008. URL: https://doi.org/10.1152/ajplung.00235.2007, doi:10.1152/ajplung.00235.2007. This article has 93 citations.

2. (komalavilas2008thesmallheat pages 1-2): Padmini Komalavilas, Raymond B. Penn, Charles R. Flynn, Jeffrey Thresher, Luciana B. Lopes, Elizabeth J. Furnish, Manhong Guo, Manuel A. Pallero, Joanne E. Murphy-Ullrich, and Colleen M. Brophy. The small heat shock-related protein, hsp20, is a camp-dependent protein kinase substrate that is involved in airway smooth muscle relaxation. American journal of physiology. Lung cellular and molecular physiology, 294 1:L69-78, Jan 2008. URL: https://doi.org/10.1152/ajplung.00235.2007, doi:10.1152/ajplung.00235.2007. This article has 93 citations.

3. (mymrikov2011largepotentialsof pages 14-16): Evgeny V. Mymrikov, Alim S. Seit-Nebi, and Nikolai B. Gusev. Large potentials of small heat shock proteins. Physiological reviews, 91 4:1123-59, Oct 2011. URL: https://doi.org/10.1152/physrev.00023.2010, doi:10.1152/physrev.00023.2010. This article has 531 citations and is from a highest quality peer-reviewed journal.

4. (mymrikov2011largepotentialsof pages 16-17): Evgeny V. Mymrikov, Alim S. Seit-Nebi, and Nikolai B. Gusev. Large potentials of small heat shock proteins. Physiological reviews, 91 4:1123-59, Oct 2011. URL: https://doi.org/10.1152/physrev.00023.2010, doi:10.1152/physrev.00023.2010. This article has 531 citations and is from a highest quality peer-reviewed journal.

5. (flynn2005transductionofphosphorylated pages 1-2): Charles R. Flynn, Colleen M. Brophy, Elizabeth J. Furnish, Padmini Komalavilas, Deron Tessier, Jeffrey Thresher, and Lokesh Joshi. Transduction of phosphorylated heat shock-related protein 20, hsp20, prevents vasospasm of human umbilical artery smooth muscle. Journal of applied physiology, 98 5:1836-45, May 2005. URL: https://doi.org/10.1152/japplphysiol.01043.2004, doi:10.1152/japplphysiol.01043.2004. This article has 34 citations and is from a domain leading peer-reviewed journal.

6. (mymrikov2011largepotentialsof pages 17-18): Evgeny V. Mymrikov, Alim S. Seit-Nebi, and Nikolai B. Gusev. Large potentials of small heat shock proteins. Physiological reviews, 91 4:1123-59, Oct 2011. URL: https://doi.org/10.1152/physrev.00023.2010, doi:10.1152/physrev.00023.2010. This article has 531 citations and is from a highest quality peer-reviewed journal.

7. (komalavilas2008thesmallheat media 8afe3440): Padmini Komalavilas, Raymond B. Penn, Charles R. Flynn, Jeffrey Thresher, Luciana B. Lopes, Elizabeth J. Furnish, Manhong Guo, Manuel A. Pallero, Joanne E. Murphy-Ullrich, and Colleen M. Brophy. The small heat shock-related protein, hsp20, is a camp-dependent protein kinase substrate that is involved in airway smooth muscle relaxation. American journal of physiology. Lung cellular and molecular physiology, 294 1:L69-78, Jan 2008. URL: https://doi.org/10.1152/ajplung.00235.2007, doi:10.1152/ajplung.00235.2007. This article has 93 citations.

8. (komalavilas2008thesmallheat media 4577aba1): Padmini Komalavilas, Raymond B. Penn, Charles R. Flynn, Jeffrey Thresher, Luciana B. Lopes, Elizabeth J. Furnish, Manhong Guo, Manuel A. Pallero, Joanne E. Murphy-Ullrich, and Colleen M. Brophy. The small heat shock-related protein, hsp20, is a camp-dependent protein kinase substrate that is involved in airway smooth muscle relaxation. American journal of physiology. Lung cellular and molecular physiology, 294 1:L69-78, Jan 2008. URL: https://doi.org/10.1152/ajplung.00235.2007, doi:10.1152/ajplung.00235.2007. This article has 93 citations.

9. (liu2018regulationofbecn1mediated pages 5-9): Guan-Sheng Liu, Hongyan Zhu, Wen-Feng Cai, Xiaohong Wang, Min Jiang, Kobina Essandoh, Elizabeth Vafiadaki, Kobra Haghighi, Chi Keung Lam, George Gardner, George Adly, Persoulla Nicolaou, Despina Sanoudou, Qiangrong Liang, Jack Rubinstein, Guo-Chang Fan, and Evangelia G. Kranias. Regulation of becn1-mediated autophagy by hspb6: insights from a human hspb6s10f mutant. Autophagy, 14:80-97, Jan 2018. URL: https://doi.org/10.1080/15548627.2017.1392420, doi:10.1080/15548627.2017.1392420. This article has 49 citations and is from a domain leading peer-reviewed journal.

10. (liu2018regulationofbecn1mediated pages 1-5): Guan-Sheng Liu, Hongyan Zhu, Wen-Feng Cai, Xiaohong Wang, Min Jiang, Kobina Essandoh, Elizabeth Vafiadaki, Kobra Haghighi, Chi Keung Lam, George Gardner, George Adly, Persoulla Nicolaou, Despina Sanoudou, Qiangrong Liang, Jack Rubinstein, Guo-Chang Fan, and Evangelia G. Kranias. Regulation of becn1-mediated autophagy by hspb6: insights from a human hspb6s10f mutant. Autophagy, 14:80-97, Jan 2018. URL: https://doi.org/10.1080/15548627.2017.1392420, doi:10.1080/15548627.2017.1392420. This article has 49 citations and is from a domain leading peer-reviewed journal.

11. (secco2024hspb6alipiddependent pages 7-9): Valentina Secco, Tatiana Tiago, Roxine Staats, Swapan Preet, Sean Chia, Michele Vendruscolo, and Serena Carra. Hspb6: a lipid-dependent molecular chaperone inhibits α-synuclein aggregation. iScience, 27:110657, Sep 2024. URL: https://doi.org/10.1016/j.isci.2024.110657, doi:10.1016/j.isci.2024.110657. This article has 6 citations and is from a peer-reviewed journal.

12. (secco2024hspb6alipiddependent pages 9-12): Valentina Secco, Tatiana Tiago, Roxine Staats, Swapan Preet, Sean Chia, Michele Vendruscolo, and Serena Carra. Hspb6: a lipid-dependent molecular chaperone inhibits α-synuclein aggregation. iScience, 27:110657, Sep 2024. URL: https://doi.org/10.1016/j.isci.2024.110657, doi:10.1016/j.isci.2024.110657. This article has 6 citations and is from a peer-reviewed journal.

13. (albinhassan2025smallheatshock pages 14-16): Tahani H. Albinhassan, Bothina Mohammed Alharbi, Entissar S. AlSuhaibani, Sameer Mohammad, and Shuja Shafi Malik. Small heat shock proteins: protein aggregation amelioration and neuro- and age-protective roles. International Journal of Molecular Sciences, 26:1525, Feb 2025. URL: https://doi.org/10.3390/ijms26041525, doi:10.3390/ijms26041525. This article has 10 citations.

14. (bonavita2025smallhspsat pages 6-7): Raffaella Bonavita, Fulvia Vitale, Luigi Vittorio Verdicchio, Sarah V. Williams, Maria Gabriella Caporaso, Angeleen Fleming, and Maurizio Renna. Small hsps at the crossroad between protein aggregation, autophagy and unconventional secretion: clinical implications and potential therapeutic opportunities in the context of neurodegenerative diseases. Frontiers in Cell and Developmental Biology, May 2025. URL: https://doi.org/10.3389/fcell.2025.1538377, doi:10.3389/fcell.2025.1538377. This article has 3 citations.

## Citations

1. mymrikov2011largepotentialsof pages 14-16
2. flynn2005transductionofphosphorylated pages 1-2
3. komalavilas2008thesmallheat pages 2-4
4. mymrikov2011largepotentialsof pages 16-17
5. mymrikov2011largepotentialsof pages 17-18
6. albinhassan2025smallheatshock pages 14-16
7. bonavita2025smallhspsat pages 6-7
8. komalavilas2008thesmallheat pages 1-2
9. https://doi.org/10.1016/j.isci.2024.110657
10. https://doi.org/10.1080/15548627.2017.1392420
11. https://doi.org/10.1152/japplphysiol.01043.2004
12. https://doi.org/10.1152/ajplung.00235.2007
13. https://doi.org/10.1152/physrev.00023.2010
14. https://doi.org/10.3389/fcell.2025.1538377
15. https://doi.org/10.3390/ijms26041525
16. https://doi.org/10.1152/ajplung.00235.2007,
17. https://doi.org/10.1152/physrev.00023.2010,
18. https://doi.org/10.1152/japplphysiol.01043.2004,
19. https://doi.org/10.1080/15548627.2017.1392420,
20. https://doi.org/10.1016/j.isci.2024.110657,
21. https://doi.org/10.3390/ijms26041525,
22. https://doi.org/10.3389/fcell.2025.1538377,